Changes to OncoSec's leadership team
This article was originally published in Scrip
OncoSec Medical, a therapeutic oncology company formed earlier this year, has appointed three members to its leadership team: Dr Michael Cross, who has nearly 20 years' experience in life sciences venture capital, has been appointed chief business officer, responsible for business development, engineering operations, partnerships and fundraising. Caryn Peterson joins as vice-president of regulatory affairs after 30 years in the pharma industry. She previously led worldwide regulatory affairs for Syndax. Veronica Vallejo will serve as controller and principal financial officer. She has a background in public accounting, most recently as senior manager with the accounting firm Mayer Hoffman McCann.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.